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Dean Baker and Adriane Fugh-Berman (2009) have published a critique of a study (Lichtenberg (2007) ) I performed in 2007, entitled "Why has longevity increased more in some states than in others?" One of the conclusions I drew from that study was that medical innovation accounts for a substantial portion of the recent increase in U.S. life expectancy. Baker and Fugh-Berman claim that my study was subject to a number of major methodological flaws. Many of their claims pertain to the role of infant mortality; the definition of drug vintage; the issue of age adjustment; and the appropriateness of controlling for AIDS, obesity, and smoking in the analysis of longevity. In this article, I
will make the case that their claims about my study are largely incorrect.
Infant mortality
Baker and Fugh-Berman make several misleading or incorrect claims related to infant mortality. First, they claimed that my study "fail[ed] to control for infant mortality." However, one of the measures I examined was life expectancy at birth, which depends on the mortality rate of infants as well as the mortality rate of older individuals. 1 Baker and Fugh-Berman also claim that "infant mortality is the single most important determinant of life expectancy." Infant mortality was not the most important determinant of the growth in U.S. life expectancy during the period that I studied. Data from the National Center for Health Statistics indicate that between 1989-1991 and 2002, life expectancy at birth increased 1.93 years, and life expectancy at age 1 increased by 1.72 years.
2 Only 11% of the increase in life expectancy at birth was due to a reduction 1 Baker and Fugh-Berman's Figure 1 shows the relationship across states between infant mortality rates and life expectancy at birth in the United States. It is unusual to show a correlation between a variable X and another variable which is calculated using X. Also, the data shown in their Figure 1 The FDA classifies all new drug applications as either priority-review or standard-review applications. A Priority Review designation is given to drugs that are expected to offer major advances in treatment, or provide a treatment where no adequate 3 As shown in Table 4 of the MI paper, during the period 1991-2004, the increase in life expectancy at age 65 was 57% as large as the increase in life expectancy at birth 4 I acknowledged in my paper that "differences in drug vintage explain some of the interstate variation in life expectancy, but the fraction of cross-sectional variance explained is smaller than the fraction of aggregate time-series variance (growth) explained." 5 The estimates reported in Table 1 allow for clustered standard errors. The estimates reported in Table 6 of Lichtenberg (2007) did not allow for clustering. 6 The vintage of a combination drug is the mean of the years in which the drug's active ingredients were first approved by the FDA.
therapy exists. Standard Review is applied to a drug that is expected to offer at most, only minor improvement over existing marketed therapies.
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As shown in the following It is therefore quite reasonable, and consistent with FDA evaluation of the therapeutic potential of new drugs, to define the vintage of a drug as the year in which the drug's active ingredient was first approved.
AIDS, obesity, and smoking
The models that I estimated adjusted for AIDS, obesity, and smoking. Baker and Fugh-Berman were critical of this. They argued that this was "an unusual set of variables."
Baker and Fugh-Berman argued that "AIDS is not among the 15 leading causes of death in any state in the U.S., so has a dubious role in this type of analysis." By that standard, infant mortality also has a dubious role: in 1995 (near the peak of the U.S.
AIDS epidemic), the number of deaths from HIV/AIDS was 43% larger than the number of infant deaths (42,337 vs. 29,583).
However, that is not a reasonable standard. The effect of a disease on life expectancy depends on the age at which people die from the disease as well as on the frequency of the disease. According to the CDC, the median age at death due to HIV disease in 1995-just before antiretroviral drugs were introduced-was 39 years.
Consequently, HIV was the fourth largest cause of years of potential life lost (YPLL) before age 65 in 1995. The first three were unintentional injuries, cancer, and heart disease. Lichtenberg ( ) provides evidence that pharmaceutical innovation has increased cancer survival rates and reduced age-adjusted cardiovascular mortality rates. This claim is not entirely accurate. Also, I will show that controlling for age does not change the basic conclusions.
The most important dependent variable in my study-life expectancy-is based on age-specific mortality rates: it controls for (is not affected by) the age distribution of the population.
Drugs in different therapeutic classes tend to be used by different age groups. For example, cardiovascular and cancer drugs tend to be used disproportionately by older people. Some of the models I estimated included a fixed-weight index of drug vintage, rather than a standard (crude) index of drug vintage. The fixed-weight vintage index controls for (holds constant) the distribution of drugs by therapeutic class, which is somewhat correlated with the distribution of drugs by age of user.
The potential bias in my estimates from failure to control for age can be assessed by including a measure of the age distribution in the longevity equation. 8 The equation
shown in column 4 of Table 1 includes the fraction of the population that is age 65 or over (old%) as a covariate. 9 The coefficient on this variable is positive but statistically insignificant. Controlling for the age distribution of the population has essentially no effect on the other coefficients. and a coding error rectified. They employed a dataset containing a broad array of health outcomes and found that when using the same instruments, the pattern of effects for specific health conditions appears to depart markedly from prominent theories of how 8 However, controlling for age in this manner runs the risk of underestimating the longevity gains from pharmaceutical innovation. If the causal mechanism is drug vintage  life expectancy  population age, holding population age constant could bias estimates of the effect of drug vintage on life expectancy downward. 9 The elderly account for about 13% of the U.S. population and about a third of U.S. pharmaceutical use.
Income, education, and longevity
education should affect health. They also found suggestive evidence that vaccination against smallpox for school age children may account for some of the improvement in health and its association with education. This raised concerns about using compulsory schooling laws to identify the causal effects of education on health.
Where do longevity gains come from?
Baker and Fugh-Berman express deep skepticism about my study's conclusion that medical innovation has played a very important role in recent U.S. longevity growth.
How, then, would they account for the U.S. experience during the period 2000-2006?
During that period, the poverty rate increased from 11.3% to 12.3%, median real household income declined about 2%, the share of Americans without health insurance increased from 13.7% to 15.8%, the fraction of Americans who were overweight or obese increased from 56.9% to 61.8% 10 --and life expectancy at birth increased by 0.9 years, from 76.8 to 77.7. Meara et al (2008) report that data from the National Longitudinal Mortality Study imply that, during the period 1991-1998, life expectancy at age 25 of people with any college education was 3.7 years higher than that of people with no college education. Data from Multiple Cause of Death files and census data imply that, in the year 2000, life expectancy at age 25 of people with any college education was 7.0 years higher than that of people with no college education 
